-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Novo Nordisk announced the company's second quarter and semi-annual report.
The report shows that the company's half-year sales increased by 25% to 83 billion Danish kroner, an increase of 16% at constant exchange rate.
Operating profit rose by 26% to DKK 35 billion, with rapid growth in the obesity care segment and product sales doubling in the first half of the yea.
The report shows that the company's half-year sales increased by 25% to 83 billion Danish kroner, an increase of 16% at constant exchange rate.
Operating profit rose by 26% to DKK 35 billion, with rapid growth in the obesity care segment and product sales doubling in the first half of the yea.
It is worth noting that the insulin business, as an advantage area of Novo Nordisk in the past, is now gon.
In the first half of 2022, Novo Nordisk's insulin business fell by 3% year-on-year to DKK 23 billio.
Insulin business in China fell particularly sharply, reaching 9%, or 17% at constant exchange rate.
The company believes that the main reason for the decline is the Chinese marke.
adopted polic.
In the first half of 2022, Novo Nordisk's insulin business fell by 3% year-on-year to DKK 23 billio.
Insulin business in China fell particularly sharply, reaching 9%, or 17% at constant exchange rate.
The company believes that the main reason for the decline is the Chinese marke.
adopted polic.
With the inclusion of traditional diabetes drugs such as insulin into centralized procurement, a lot of economic burdens have been reduced for diabetic patients, but at the same time, the profit margins of listed companies in the insulin industry have been squeeze.
In the face of price and market changes, local companies are also not immun.
Tonghua Dongbao and Gan & Lee Pharmaceuticals, known as the "double heroes of insulin", have also encountered huge challenges in the structural adjustment of the insulin marke.
In the face of price and market changes, local companies are also not immun.
Tonghua Dongbao and Gan & Lee Pharmaceuticals, known as the "double heroes of insulin", have also encountered huge challenges in the structural adjustment of the insulin marke.
In this context, how should pharmaceutical companies related to diabetes reshape the performance growth curve?
In recent years, new hypoglycemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists, have shown strong competitiveness, not only in the field of diabetes treatment, but also in metabolic diseases such as weight los.
Industry experts generally believe that with the rapid growth of GLP-1 in the overseas weight loss market, imported products represented by companies such as Novo Nordisk and Eli Lilly will extend the "weight loss" indications to the domestic market, superimposing Gan & Lee Pharmaceutical.
, Tonghua Dongbao, Cinda, Hengrui, Huadong Medicine and other local companies have rapidly deployed, and the real demand in the field of weight loss that was neglected due to the "narrow track" in the past seems to be far greater than the traditional concep.
The management market may soon usher in a situation where gunpowder smoke is everywher.
, Tonghua Dongbao, Cinda, Hengrui, Huadong Medicine and other local companies have rapidly deployed, and the real demand in the field of weight loss that was neglected due to the "narrow track" in the past seems to be far greater than the traditional concep.
The management market may soon usher in a situation where gunpowder smoke is everywher.
Insulin centralized procurement is fully implemented
Stimulate pharmaceutical companies to accelerate product transformation
In 2021, the International Diabetes Federation (IDF) released the "IDF World Diabetes Map (10th Edition)", showing that the number of adults with diabetes worldwide will reach 537 million (15%) in 2021. In the past 10 years, the number of diabetic patients in China has increased from 90 million to 141 millio.
On November 30, 2021, the Office of Joint Drug Purchasing of the State Organization issued the "Notice on Announcement of the Selection Results of the National Centralized Drug Purchasing (Insulin Special).
Eight months after the results of the special centralized procurement of insulin were released, the full implementation of all provinces and cities across the country was finally achieved on July 4, 2022. It is reported that the first-year procurement demand of medical institutions nationwide is about 210 millio.
Based on the price before the centralized procurement, the purchase amount involved is about 17 billion yua.
The average price of the selected products is reduced by 48.
It is expected to save a total of 9 billion for patients every yea.
Yuan Renminb.
Eight months after the results of the special centralized procurement of insulin were released, the full implementation of all provinces and cities across the country was finally achieved on July 4, 2022. It is reported that the first-year procurement demand of medical institutions nationwide is about 210 millio.
Based on the price before the centralized procurement, the purchase amount involved is about 17 billion yua.
The average price of the selected products is reduced by 48.
It is expected to save a total of 9 billion for patients every yea.
Yuan Renminb.
Recently, Tonghua Dongbao and Gan & Lee Pharmaceuticals, the leading companies in the insulin market, disclosed their forecasts for the first half of 2022.
Tonghua Dongbao expects net profit in the first half of this year to be 191 billion yuan, a year-on-year increase of 774.
However, non-net profit is expected to decline by 336% year-on-yea.
The reason why the net profit can increase significantly is mainly because Tonghua Dongbao sold some shares of Xiamen Tebao Biological Engineering C.
, Lt.
, and the deduction of non-net profit reflects the real situation of its main busines.
However, non-net profit is expected to decline by 336% year-on-yea.
The reason why the net profit can increase significantly is mainly because Tonghua Dongbao sold some shares of Xiamen Tebao Biological Engineering C.
, Lt.
, and the deduction of non-net profit reflects the real situation of its main busines.
Gan and Lee Pharmaceuticals, which is also the industry leader, fell directly into losse.
Gan & Lee Pharmaceutical expects to lose 168 million to 200 million yuan in the first half of this year, turning from profit to loss year-on-yea.
This is also the first loss since Gan & Lee's listin.
Gan & Lee Pharmaceutical expects to lose 168 million to 200 million yuan in the first half of this year, turning from profit to loss year-on-yea.
This is also the first loss since Gan & Lee's listin.
For the main reason for the pre-loss in performance, the two companies are attributed to the implementation of the national special centralized procurement of insulin and the decline in the price of insulin product.
In order to speed up getting rid of the influence of centralized procurement, Tonghua Dongbao and Ganli Pharmaceutical have both accelerated the process of new drug research and developmen.
GLP-1 receptor agonist drugs are a hot research and development direction of many domestic and foreign pharmaceutical companies in the field of hypoglycemic drugs:
GLP-1 receptor agonist drugs are a hot research and development direction of many domestic and foreign pharmaceutical companies in the field of hypoglycemic drugs:
On June 9, Tonghua Dongbao announced that the company's application for the registration of the marketing authorization of liraglutide injection has been accepted by the State Drug Administratio.
Liraglutide is a human glucagon-like peptide-1 (GLP-1) analog developed by Novo Nordis.
It entered the Chinese market in 2011 and was approved for the control of blood sugar in adults with type 2 diabete.
. In addition, liraglutide also has a significant weight loss effect, and the product for weight loss indications (Saxenda) was launched in the United States in December 2014.
Liraglutide is a human glucagon-like peptide-1 (GLP-1) analog developed by Novo Nordis.
It entered the Chinese market in 2011 and was approved for the control of blood sugar in adults with type 2 diabete.
. In addition, liraglutide also has a significant weight loss effect, and the product for weight loss indications (Saxenda) was launched in the United States in December 2014.
On July 22, Gan & Lee Pharmaceuticals announced that the self-developed GZR18 was undergoing Phase II clinical trials in China, and the first subject was successfully administered recentl.
The drug is a weekly preparation of glucagon-like peptide-1 (GLP-1) receptor agonist independently developed by Gan & Lee Pharmaceutical.
The drug is a weekly preparation of glucagon-like peptide-1 (GLP-1) receptor agonist independently developed by Gan & Lee Pharmaceutical.
Since Novo Nordisk developed the first-generation GLP-1 analog liraglutide (Novoli) for weight loss indications in 2014, it has become a representative of a new generation of weight loss drugs, and participants have also smelled GLP-1 excitemen.
The huge market prospect of the agen.
The huge market prospect of the agen.
At present, the GLP-1 receptor agonist drugs that have been marketed in the world are mainly as follows:
Weight management is in high demand
GLP-1 market prospects?
In fact, GLP-1 receptor agonists enhance insulin secretion and inhibit glucagon secretion in a glucose concentration-dependent manner, thus lowering blood glucose without significantly increasing the risk of hypoglycemi.
At the same time, GLP-1 receptor agonists can reduce body weight by delaying gastric emptying and central appetite suppressio.
In addition, a number of large-scale clinical studies such as LEADER, SUSTAIN, and REWIND have shown that GLP-1 receptor agonists such as liraglutide, semaglutide and dulaglutide have a significant effect on reducing the risk of major cardiovascular event.
At the same time, GLP-1 receptor agonists can reduce body weight by delaying gastric emptying and central appetite suppressio.
In addition, a number of large-scale clinical studies such as LEADER, SUSTAIN, and REWIND have shown that GLP-1 receptor agonists such as liraglutide, semaglutide and dulaglutide have a significant effect on reducing the risk of major cardiovascular event.
With the acceleration and expansion of medical insurance centralized procurement, it is only a matter of time before GLP-1 drugs are reduced to centralized procurement and included in the medical insurance catalo.
For pharmaceutical companies with diabetes pipelines, they need to have enough fighting ability before the sword of Damocles falls, and the development of new indications for GLP-1 drugs has become an important layout for the.
For pharmaceutical companies with diabetes pipelines, they need to have enough fighting ability before the sword of Damocles falls, and the development of new indications for GLP-1 drugs has become an important layout for the.
Adding new indications is an important strategy for drug clinical developmen.
With the large investment of many companies, more and more GLP-1 drugs will be developed for metabolic syndrome-related adaptations in addition to the treatment of type 2 diabete.
diseases, such as obesit.
With the large investment of many companies, more and more GLP-1 drugs will be developed for metabolic syndrome-related adaptations in addition to the treatment of type 2 diabete.
diseases, such as obesit.
According to the Dietary Guidelines for Chinese Residents (2022), the current overweight and obesity rates of residents aged 18 and over in China are 33% and 14%, respectively, and the problems of overweight, obesity and chronic diseases are becoming more and more seriou.
At present, most of the treatments for obesity are still based on exercise + dietary interventio.
However, "shut your mouth and open your legs" is always easier said than don.
There is an urgent need for a drug that can easily lose weight by taking medication or injections, and also improve various body indicator.
However, "shut your mouth and open your legs" is always easier said than don.
There is an urgent need for a drug that can easily lose weight by taking medication or injections, and also improve various body indicator.
There have been many weight loss drugs on the market, but most of them have been banned due to damage to the central nervous system or cardiovascular and cerebrovascula.
At present, the only approved weight loss drug in China is orlista.
Its principle is to reduce the absorption of fat in the gastrointestinal tract, but it is often accompanied by gastrointestinal symptoms such as diarrhe.
At present, the only approved weight loss drug in China is orlista.
Its principle is to reduce the absorption of fat in the gastrointestinal tract, but it is often accompanied by gastrointestinal symptoms such as diarrhe.
Although some diabetes drugs can cause weight loss (such as metformin, semaglutide, et.
), the current indications are only for the treatment of type 2 diabete.
), the current indications are only for the treatment of type 2 diabete.
The growing market demand for weight loss, combined with the relative lack of weight loss drugs at present, makes weight control drugs still a blue ocean in Chin.
With the development of liraglutide in weight loss indications, Novo Nordisk has gained huge market share and commercial success in overseas markets; in June 2021, it will take over the next-generation GLP-1 star variety of liraglutide "Semaglutide" was approved by the US FDA for chronic weight management, which further attracted market attentio.
At the same time, as the core patent of liraglutide is about to expire, the market demand for weight management is gradually opened, attracting more and more pharmaceutical companies to gear u.
At present, Eli Lilly's Tirzepatide is the fastest-growing dual-target GLP-1 drug in clinical development and has entered the phase III trial stag.
Overseas phase III clinical data show that in the "head-to-head" trial with semaglutide, Tirzepatide used 5mg, 10mg, and 15mg of subjects with an average weight loss of 16%, 24%, and 25% in 72 weeks, respectivel.
%, which exceeded the weight loss effect of semaglutide and caused a sensation in the industr.
Overseas phase III clinical data show that in the "head-to-head" trial with semaglutide, Tirzepatide used 5mg, 10mg, and 15mg of subjects with an average weight loss of 16%, 24%, and 25% in 72 weeks, respectivel.
%, which exceeded the weight loss effect of semaglutide and caused a sensation in the industr.
The Chinese market is also ready to g.
According to Wanlian Securities data, China's weight management product market is expected to reach 6 billion yuan in 2025, with a CAGR (average compound annual growth rate) of 32% from 2020 to 2025; 26 billion yuan in 2030, and a CAGR of 21% from 2025 to 2030.
According to Wanlian Securities data, China's weight management product market is expected to reach 6 billion yuan in 2025, with a CAGR (average compound annual growth rate) of 32% from 2020 to 2025; 26 billion yuan in 2030, and a CAGR of 21% from 2025 to 2030.
At present, there is no GLP-1 agonist weight-loss product on the market in Chin.
In order to share the weight-loss market and actively save themselves for innovation and transformation, many pharmaceutical companies with diabetes pipelines have started research and developmen.
Renhui Bio and Huadong Medicine, which are at the forefront, have There are products in the production stage, which are expected to become the first domestically produced innovative weight loss drug.
In order to share the weight-loss market and actively save themselves for innovation and transformation, many pharmaceutical companies with diabetes pipelines have started research and developmen.
Renhui Bio and Huadong Medicine, which are at the forefront, have There are products in the production stage, which are expected to become the first domestically produced innovative weight loss drug.
On March 11 this year, Renhui Bio announced that the Center for Drug Evaluation (CDE) of the State Food and Drug Administration has accepted the registration and marketing of BEM-014 (new indication of benaglutide injection in the field of weight loss) "domestic production drug " application for permission.
It was followed by Huadong Medicin.
On the evening of July 13, Huadong Medicine announced that the application for the marketing authorization of liraglutide injection for obesity or overweight indications submitted by a wholly-owned subsidiary was accepte.
On the evening of July 13, Huadong Medicine announced that the application for the marketing authorization of liraglutide injection for obesity or overweight indications submitted by a wholly-owned subsidiary was accepte.
In addition, there are many pharmaceutical companies developing GLP-1 agonist pipelines, and many domestic pharmaceutical companies such as Wanbang Bio, Innovent Bio, Dongyang Sunshine, and Hansoh have already deploye.
Some are developing generics of liraglutide, some are developing other GLP-1 agonists, and many pharmaceutical companies have seized the opportunity and entered the era of dual target.
Some are developing generics of liraglutide, some are developing other GLP-1 agonists, and many pharmaceutical companies have seized the opportunity and entered the era of dual target.
picture
"At present, no GLP-1 product has been approved for weight loss indications in China, and from the perspective of clinical drug indications, the premise of GLP-1 for the treatment of obesity is obese patients with diabetes, and there are also clear requirements for body mass inde.
Do not use blindl.
" Clinical experts said that the abuse of GLP-1 drugs that do not meet the drug indications is likely to lead to other drug risks, and European and American drug regulatory authorities have also issued warnings about thi.
Do not use blindl.
" Clinical experts said that the abuse of GLP-1 drugs that do not meet the drug indications is likely to lead to other drug risks, and European and American drug regulatory authorities have also issued warnings about thi.
Now that the diabetes pipeline companies whose main business is under pressure are fighting with each other, who can win the first place in the domestic GLP-1 weight loss indications in the future? Who can occupy the largest market share? Let's wait and se.
A few days ago, Novo Nordisk announced the company's second quarter and semi-annual report.
The report shows that the company's half-year sales increased by 25% to 83 billion Danish kroner, an increase of 16% at constant exchange rate.
Operating profit rose by 26% to DKK 35 billion, with rapid growth in the obesity care segment and product sales doubling in the first half of the yea.
The report shows that the company's half-year sales increased by 25% to 83 billion Danish kroner, an increase of 16% at constant exchange rate.
Operating profit rose by 26% to DKK 35 billion, with rapid growth in the obesity care segment and product sales doubling in the first half of the yea.
It is worth noting that the insulin business, as an advantage area of Novo Nordisk in the past, is now gon.
In the first half of 2022, Novo Nordisk's insulin business fell by 3% year-on-year to DKK 23 billio.
Insulin business in China fell particularly sharply, reaching 9%, or 17% at constant exchange rate.
The company believes that the main reason for the decline is the Chinese marke.
adopted polic.
In the first half of 2022, Novo Nordisk's insulin business fell by 3% year-on-year to DKK 23 billio.
Insulin business in China fell particularly sharply, reaching 9%, or 17% at constant exchange rate.
The company believes that the main reason for the decline is the Chinese marke.
adopted polic.
With the inclusion of traditional diabetes drugs such as insulin into centralized procurement, a lot of economic burdens have been reduced for diabetic patients, but at the same time, the profit margins of listed companies in the insulin industry have been squeeze.
In the face of price and market changes, local companies are also not immun.
Tonghua Dongbao and Gan & Lee Pharmaceuticals, known as the "double heroes of insulin", have also encountered huge challenges in the structural adjustment of the insulin marke.
In the face of price and market changes, local companies are also not immun.
Tonghua Dongbao and Gan & Lee Pharmaceuticals, known as the "double heroes of insulin", have also encountered huge challenges in the structural adjustment of the insulin marke.
In this context, how should pharmaceutical companies related to diabetes reshape the performance growth curve?
In recent years, new hypoglycemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists, have shown strong competitiveness, not only in the field of diabetes treatment, but also in metabolic diseases such as weight los.
Industry experts generally believe that with the rapid growth of GLP-1 in the overseas weight loss market, imported products represented by companies such as Novo Nordisk and Eli Lilly will extend the "weight loss" indications to the domestic market, superimposing Gan & Lee Pharmaceutical.
, Tonghua Dongbao, Cinda, Hengrui, Huadong Medicine and other local companies have rapidly deployed, and the real demand in the field of weight loss that was neglected due to the "narrow track" in the past seems to be far greater than the traditional concep.
The management market may soon usher in a situation where gunpowder smoke is everywher.
Pharmaceutical and pharmaceutical enterprises, Tonghua Dongbao, Cinda, Hengrui, Huadong Medicine and other local companies have rapidly deployed, and the real demand in the field of weight loss that was neglected due to the "narrow track" in the past seems to be far greater than the traditional concep.
The management market may soon usher in a situation where gunpowder smoke is everywher.
Insulin centralized procurement is fully implemented
Insulin centralized procurement is fully implemented Stimulate pharmaceutical companies to accelerate product transformation
Stimulate pharmaceutical companies to accelerate product transformation In 2021, the International Diabetes Federation (IDF) released the "IDF World Diabetes Map (10th Edition)", showing that the number of adults with diabetes worldwide will reach 537 million (15%) in 2021. In the past 10 years, the number of diabetic patients in China has increased from 90 million to 141 millio.
On November 30, 2021, the Office of Joint Drug Purchasing of the State Organization issued the "Notice on Announcement of the Selection Results of the National Centralized Drug Purchasing (Insulin Special).
Eight months after the results of the special centralized procurement of insulin were released, the full implementation of all provinces and cities across the country was finally achieved on July 4, 2022. It is reported that the first-year procurement demand of medical institutions nationwide is about 210 millio.
Based on the price before the centralized procurement, the purchase amount involved is about 17 billion yua.
The average price of the selected products is reduced by 48.
It is expected to save a total of 9 billion for patients every yea.
Yuan Renminb.
purchase purchaseEight months after the results of the special centralized procurement of insulin were released, the full implementation of all provinces and cities across the country was finally achieved on July 4, 2022. It is reported that the first-year procurement demand of medical institutions nationwide is about 210 millio.
Based on the price before the centralized procurement, the purchase amount involved is about 17 billion yua.
The average price of the selected products is reduced by 48.
It is expected to save a total of 9 billion for patients every yea.
Yuan Renminb.
Recently, Tonghua Dongbao and Gan & Lee Pharmaceuticals, the leading companies in the insulin market, disclosed their forecasts for the first half of 2022.
Tonghua Dongbao expects net profit in the first half of this year to be 191 billion yuan, a year-on-year increase of 774.
However, non-net profit is expected to decline by 336% year-on-yea.
The reason why the net profit can increase significantly is mainly because Tonghua Dongbao sold some shares of Xiamen Tebao Biological Engineering C.
, Lt.
, and the deduction of non-net profit reflects the real situation of its main busines.
However, non-net profit is expected to decline by 336% year-on-yea.
The reason why the net profit can increase significantly is mainly because Tonghua Dongbao sold some shares of Xiamen Tebao Biological Engineering C.
, Lt.
, and the deduction of non-net profit reflects the real situation of its main busines.
Gan and Lee Pharmaceuticals, which is also the industry leader, fell directly into losse.
Gan & Lee Pharmaceutical expects to lose 168 million to 200 million yuan in the first half of this year, turning from profit to loss year-on-yea.
This is also the first loss since Gan & Lee's listin.
Gan & Lee Pharmaceutical expects to lose 168 million to 200 million yuan in the first half of this year, turning from profit to loss year-on-yea.
This is also the first loss since Gan & Lee's listin.
For the main reason for the pre-loss in performance, the two companies are attributed to the implementation of the national special centralized procurement of insulin and the decline in the price of insulin product.
In order to speed up getting rid of the influence of centralized procurement, Tonghua Dongbao and Ganli Pharmaceutical have both accelerated the process of new drug research and developmen.
GLP-1 receptor agonist drugs are a hot research and development direction of many domestic and foreign pharmaceutical companies in the field of hypoglycemic drugs:
GLP-1 receptor agonist drugs are a hot research and development direction of many domestic and foreign pharmaceutical companies in the field of hypoglycemic drugs:
On June 9, Tonghua Dongbao announced that the company's application for the registration of the marketing authorization of liraglutide injection has been accepted by the State Drug Administratio.
Liraglutide is a human glucagon-like peptide-1 (GLP-1) analog developed by Novo Nordis.
It entered the Chinese market in 2011 and was approved for the control of blood sugar in adults with type 2 diabete.
. In addition, liraglutide also has a significant weight loss effect, and the product for weight loss indications (Saxenda) was launched in the United States in December 2014.
Liraglutide is a human glucagon-like peptide-1 (GLP-1) analog developed by Novo Nordis.
It entered the Chinese market in 2011 and was approved for the control of blood sugar in adults with type 2 diabete.
. In addition, liraglutide also has a significant weight loss effect, and the product for weight loss indications (Saxenda) was launched in the United States in December 2014.
On July 22, Gan & Lee Pharmaceuticals announced that the self-developed GZR18 was undergoing Phase II clinical trials in China, and the first subject was successfully administered recentl.
The drug is a weekly preparation of glucagon-like peptide-1 (GLP-1) receptor agonist independently developed by Gan & Lee Pharmaceutical.
The drug is a weekly preparation of glucagon-like peptide-1 (GLP-1) receptor agonist independently developed by Gan & Lee Pharmaceutical.
Since Novo Nordisk developed the first-generation GLP-1 analog liraglutide (Novoli) for weight loss indications in 2014, it has become a representative of a new generation of weight loss drugs, and participants have also smelled GLP-1 excitemen.
The huge market prospect of the agen.
The huge market prospect of the agen.
At present, the GLP-1 receptor agonist drugs that have been marketed in the world are mainly as follows:
Weight management is in high demand
Weight management is in high demand GLP-1 market prospects?
GLP-1 market prospects? ，GLP-1、，
。，GLP-1、
。，LEADER、SUSTAIN、REWIND，、GLP-1
。
。，GLP-1、
。，LEADER、SUSTAIN、REWIND，、GLP-1
。
，GLP-1、
。，，，GLP-1
。
。，，，GLP-1
。
，，GLP-12，
。
。
《（2022）》，18，33%14%，
。
。
，+，，“、”，
。，
。
。，
。
，，
。，，
。
。，，
。
（、），2
。
。
，，
。
。
，；20216，GLP-1“”FDA，
。
。
，，，
。
。
，TirzepatideGLP-1，Ⅲ
。Ⅲ，“”，Tirzepatide72，5mg、10mg、15mg16%、24%、25%，，
。
。Ⅲ，“”，Tirzepatide72，5mg、10mg、15mg16%、24%、25%，，
。
。，202596，2020～2025CAGR（）32%；2030260，2025～2030CAGR21%
。
。
，GLP-1，，，，、，
。
。
On March 11 this year, Renhui Bio announced that the Center for Drug Evaluation (CDE) of the State Food and Drug Administration has accepted the registration and marketing of BEM-014 (new indication of benaglutide injection in the field of weight loss) "domestic production drug " application for permission.
drug registration drug registration It was followed by Huadong Medicin.
On the evening of July 13, Huadong Medicine announced that the application for the marketing authorization of liraglutide injection for obesity or overweight indications submitted by a wholly-owned subsidiary was accepte.
On the evening of July 13, Huadong Medicine announced that the application for the marketing authorization of liraglutide injection for obesity or overweight indications submitted by a wholly-owned subsidiary was accepte.
In addition, there are many pharmaceutical companies developing GLP-1 agonist pipelines, and many domestic pharmaceutical companies such as Wanbang Bio, Innovent Bio, Dongyang Sunshine, and Hansoh have already deploye.
Some are developing generics of liraglutide, some are developing other GLP-1 agonists, and many pharmaceutical companies have seized the opportunity and entered the era of dual target.
Some are developing generics of liraglutide, some are developing other GLP-1 agonists, and many pharmaceutical companies have seized the opportunity and entered the era of dual target.
picture
picture "At present, no GLP-1 product has been approved for weight loss indications in China, and from the perspective of clinical drug indications, the premise of GLP-1 for the treatment of obesity is obese patients with diabetes, and there are also clear requirements for body mass inde.
Do not use blindl.
" Clinical experts said that the abuse of GLP-1 drugs that do not meet the drug indications is likely to lead to other drug risks, and European and American drug regulatory authorities have also issued warnings about thi.
medicines _Do not use blindl.
" Clinical experts said that the abuse of GLP-1 drugs that do not meet the drug indications is likely to lead to other drug risks, and European and American drug regulatory authorities have also issued warnings about thi.
Now that the diabetes pipeline companies whose main business is under pressure are fighting with each other, who can win the first place in the domestic GLP-1 weight loss indications in the future? Who can occupy the largest market share? Let's wait and se.
